Board summary
Key figures
64,491
Registered population
59.3% aged 18–64
18.6%
Aged 65+
ICB 14.9% · England 17.9%
14.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~8,845
Core20 residents (est.)
Resident basis; registered basis ~9,555 · see page 3
10,211
Hypertension register
+4.46% in 3 yrs · England +5.60%
692
SMI register
25.8% of Trafford (LAD)'s
1,285
COPD register
Reviews -5.21% in 3 yrs
Forecast to 2030
11,209
Hypertension patients, 2030
+998 on today
72.1%
QRISK ≥20% on statins, 2030
+3.06pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Three-year review and blood pressure control lags.
Of 25 measures, 19 trail England's three-year change: heart failure reviews fell 2.9%, COPD reviews fell 5.2%, and under-80 BP control fell 0.7%.
Strong cancer screening and heart failure reviews.
Cervical screening aged 25-49 reaches 77.1% (England 66.8%), breast screening reaches 75.1% (England 69.9%), and heart failure reviews reach 80.7% (England 78.5%).
Population, age and ethnicity
Aged 0-17 (22.1%) and 65+ (18.6%) list shares both exceed England benchmarks
Across five member practices totalling 64,491 registered patients, children aged 0-17 represent 22.1% (14,243 patients), exceeding Trafford (21.8%), the ICB (21.8%) and England (19.6%). Older adults aged 65+ make up 18.6% (11,980 patients), above Trafford (17.1%), the ICB (14.9%) and England (17.9%), while adults aged 18-64 form 59.3% (38,268). In Census resident estimates, Gypsy or Irish Traveller residents comprise 0.0% (Trafford 0.0%, ICB 0.1%, England 0.1%) and Roma 0.1% (Trafford 0.1%, ICB 0.1%, England 0.2%). Unverified projections indicate 0.4% list growth to 2030 (Trafford 0.3%, ICB 1.6%, England 2.3%).
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Trafford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Trafford LA) | 2,087 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Trafford LA) | 950 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Trafford LA) | 22.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 share is 14.6%, but practice concentration spans 42.0 pp
Sale Central PCN's Core20 share is 14.6%, above Trafford's 8.2% but below England's 21.0% and the ICB's 40.7%. Practice Core20 concentration spans 42.0 pp across the PCN: Boundary House Medical Centre records 42.05% (4,658 estimated patients), Firsway Health Centre has 20.94% (3,173 patients), and Washway Road Medical Centre records 0.0%. Resident Core20 estimates of 8,845 do not match practice-modelled totals summing to 9,555. Concentration of Core20 patients in Boundary House Medical Centre and Firsway Health Centre highlights where targeted health equity initiatives would reach the largest cohorts.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
692
SMI register
1.06% recorded prevalence
313
Learning disability register
0.48% recorded prevalence
23
Care homes, 558 beds
In the PCN catchment
8.7%
Provide unpaid care
Trafford (LAD), Census 2021
The SMI register records 692 patients (1.1%; Trafford 1.1%, ICB 1.1%, England 1.0%) and learning disability 313 (0.5%; Trafford 0.5%, ICB 0.6%, England 0.6%). Catchment services include 23 care homes (558 beds). Borough data shows an 8.7% unpaid care ceiling (5,611) and 8 rough sleepers in autumn 2025. Lower recorded learning disability prevalence than England (0.6%) may reflect differing recording practices, which clinical audit could test.
Severe mental illness: physical health checks
SMI health checks show blood pressure recorded at 90.3% (England 83.4%) and BMI at 89.5% (England 82.1%). Blood pressure check three-year gains rose +2.4 pp (England +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,211
Hypertension register
+4.46%
Register growth, 3 yrs
Trafford (LAD) +4.39% · England +5.60%
−0.50pp
BP control, under 80
≤140/90 · +3.76pp aged 80+
+998
More patients by 2030
Forecast 11,209 (16.99%)
Hypertension case-finding and control
Sale Central PCN records 10,211 hypertension patients (15.6% prevalence; England 15.2%, Trafford 15.1%). Among patients with hypertension, 93.0% had a recent blood pressure check (England 90.0%). For patients aged under 80, blood pressure control is 67.7% (England 67.8%) and fell 0.7% over three years (England +3.2%). Control for patients aged 80 and over rose +4.6% to 85.2% (England 81.2%). Across 830 heart failure patients, reviews reached 80.7% (England 78.5%), though reviews fell 2.9% over three years (England +8.7%). Slower three-year progress in blood pressure control for younger cohorts and heart failure reviews could reflect recall pressures.
Lipids and statins
Among patients with QRISK at or above 20%, lipid-lowering therapy coverage is 65.5% (England 63.6%, Trafford 67.1%). For patients with chronic kidney disease, lipid-lowering therapy coverage is 70.2% (England 70.3%, Trafford 71.2%). Coverage trails borough benchmarks, indicating potential to expand primary prevention reviews across high-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 121,407 | £2.20 | £1.94 | £1.86 | £267,095 |
| Cardiovascular (all), 2025 | 171,306 | £2.82 | £3.15 | £3.33 | £483,083 |
In 2026, the PCN prescribed 121,407 items for lipid-regulating drugs at £2.20 per item, compared with £1.86 in England, £1.98 in Trafford, and £1.94 in the ICB. Across these items, the PCN spends £41,278 more than at England's unit cost. Unit-cost differences could reflect formulary choices or medication mix, warranting a local prescribing review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.11%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.68%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.0% (1,285 patients; NHS Greater Manchester Integrated Care Board 2.3%), but reviews fell 5.2% over three years (England +2.8%) to 75.6% (England 76.4%). Asthma prevalence is 7.5% (4,664 patients; England 6.6%); reviews rose 0.1% over three years (England +4.4%) to 69.7% (England 65.7%), leaving an unreviewed scale indicator of 1,413 patients. Second-hand smoke recording for asthma patients aged 6-19 is 71.6% (England 78.8%). Three-year review lags may indicate capacity constraints in routine respiratory follow-up.
Cancer register and children's immunisation
Cancer prevalence is 4.5% (2,944 patients; England 3.8%), with three-year growth of +5.7% (England +9.0%). In Q1 2025/26 childhood immunisations at age 5, MMR dose 1 reached 95.3%, while MMR dose 2 was 90.1% (5.2 pp below dose 1 and below the 95.0% target by 4.9 pp). The 4-in-1 booster reached 86.6%, below the 95.0% target by 8.4 pp. Booster coverage lags behind first-dose uptake across pre-school cohorts.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, compared to England (55.3%) and 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% of registered cancers (11,679 of 16,492; England 67.0%). Reaching the ambition across the ICB would require about 2,270 additional early-stage diagnoses annually based on 2022 staged cases. In Sale Central PCN, recorded cancer prevalence is 4.5% (2,944 patients), with three-year register growth of +5.7% trailing England (+9.0%) and Trafford (+7.8%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the 62-day cancer referral to treatment standard, trailing Northern Care Alliance NHS Foundation Trust (78.6%), Stockport NHS Foundation Trust (74.7%) and NHS Greater Manchester Integrated Care Board (75.7%), but exceeding England (71.2%) while sitting 12.2 pp below the 85.0% standard. For six-week diagnostic waits, Manchester University NHS Foundation Trust recorded 14.7% for CT (Stockport 2.9%, Northern Care Alliance 4.1%, England 9.9%) and 11.7% for MRI. These provider metrics reflect wider acute system activity rather than direct PCN performance.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Stockport | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 83.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 97.39 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 74.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Stockport | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 1.41 | 21.40 |
| CT | 14.66 | 4.10 | 2.93 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 17.46 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 5.53 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.31 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 14.08 | 23.14 |
| Community services activity | Trafford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 41,705 | 573,310 |
| Referrals | 7,445 | 94,470 |
| Patients with a contact | 13,840 | 183,535 |
Community services (residents of Trafford), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts for Trafford borough residents totalled 41,705, of which 21,375 (51.3%) were with adults aged 65 and over. These figures describe local authority resident contacts rather than PCN-level provision.
Practice variation and patient experience
Vaccination domain achievement varies by 27.4 pp across member practices in 2025/26
In 2025/26, overall QOF achievement ranges from 92.0% at Bodmin Road Health Centre to 98.2% at Conway Road Medical Practice (England 92.5%). Vaccination and immunisation achievement varies by 27.4 pp, from 57.1% at Boundary House Medical Centre to 84.5% at Conway Road Medical Practice (England 55.2%), which may reflect differing recall or uptake dynamics requiring local audit.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Boundary House | 102 | 42.0 | 88.7% | 74.2% | 90.4% |
| Washway Road | 104 | 0.0 | 79.8% | 78.6% | 87.5% |
| Conway Road | 98 | 6.1 | 84.6% | 86.0% | 85.9% |
| Bodmin Road | 107 | 10.2 | 72.1% | 83.9% | 82.9% |
| Firsway | 116 | 20.9 | 62.2% | 82.5% | 78.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
19 of 25 measures trail England on three-year progress despite strong snapshot achievement
While Sale Central PCN achieves strong current reach—including heart failure reviews at 80.7% (England 78.5%) and non-frail diabetes HbA1c control at 60.7% (England 57.4%)—19 of 25 measures trail England over three years. Heart failure reviews fell 2.9% (England +8.7%), COPD reviews fell 5.2% (England +2.8%), and non-frail diabetes control rose 0.1% (England +4.4%). Conversely, breast screening rose 10.9% (England +8.4%) and cervical screening rose 0.6% (England -1.0%). Slower review progress could reflect recall capacity pressures, requiring local audit to verify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Diabetes HbA1c control
Asthma reviews
BP control, under 80
Breast screening (53-70)
BP control, 80+
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Trafford (LAD) | Asset | PCN | Trafford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 23 (558 beds) | n/a | Schools (catchment) | 46 | n/a |
| Children's centres | 5 | 16 | Places of worship | 25 | 119 |
| Libraries | 2 | 9 | Primary schools (LA maintained) | 14 | 39 |
| Primary academies | 5 | 17 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and smoke recording
Asthma review coverage is 69.7% across 4,664 patients (+0.1% 3-year change vs England +4.4%), leaving a 1,413-patient unreviewed scale estimate; age 6-19 second-hand smoke recording is 71.6% (England 78.8%). For discussion: run a single-template asthma recall and inhaler review with after-school slots for ages 6-19, starting in high-Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension control and lipid review
Under-80 BP control is 67.7% (England 67.8%), falling 0.7% (0.5 pp) over 3 years (England +3.2%, +2.1 pp). Lipid-modifying drugs cost £2.20 per item vs £1.86 in England (£41,278 more across 121,407 items). For discussion: deploy pharmacist-led recall for under-80 hypertension patients above target alongside a formulary and statin review. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Learning disability register coding validation
Learning disability prevalence is 0.5% (313 patients, 26% of Trafford's register, +8.2% 3-year change), matching Trafford (0.5%) but 0.1 pp below England and the ICB (0.6%), giving a -1 to +66 benchmark range. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dual cohort capacity planning (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check recall audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register review and audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma review and smoke recording (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension control and lipid review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Cost per item for Lipid-regulating drugs 2026 | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Learning disability register coding validation (p12) | Registered population · Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
